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OBJECTIVES The purpose of this study was to evaluate the rate of recognition of atrial fibrillation (AF), use
of warfarin and prevalence of cerebrovascular accident (CVA) in paced versus unpaced
patients during admission to a tertiary care teaching hospital.
BACKGROUND The presence of AF underlying a continuously paced rhythm may be under recognized and
result in a lower rate of anticoagulation and higher incidence of CVA.
METHODS The identification of AF on 12 lead electrocardiogram (ECG) and telemetry, “optimal use”
of anticoagulants that is, warfarin or aspirin, when warfarin is contraindicated and history of
prior CVA was studied in three groups: 1) group A with continuously paced rhythm on ECG
and telemetry (n 5 30), 2) group B with intermittently paced rhythm on ECG and telemetry
(n 5 59), and 3) group C with persistent AF and no permanent pacemaker (n 5 50).
RESULTS The identification and documentation of AF was significantly lower in the continuously paced
group A (20%) versus the intermittently paced group B (44%). Both groups A and B were
substantially lower than unpaced controls. “Optimal use” of anticoagulants was significantly
lower in group A (40%) compared with groups B (78%) and C (72%) but was not different
between groups B and C. The prevalence of prior CVA was not significantly different
between the three groups.
CONCLUSIONS All ECGs in patients with paced rhythm should be examined closely for underlying AF to
prevent under-recognition and under-treatment with anticoagulants. (J Am Coll Cardiol
2000;36:784–7) © 2000 by the American College of Cardiology
The role of anticoagulation to prevent thromboembolic
events in patients with nonrheumatic atrial fibrillation (AF)
is well established (1–9). Pacemaker recipients are by and
large an elderly population with underlying heart disease
and a high prevalence of AF (10). The diagnosis of AF is
often based on the recognition of an irregularly irregular
rhythm. We hypothesized that the absence of an irregular
rhythm in paced patients may result in a decreased recog-
nition of underlying AF, a lower rate of anticoagulation and
a higher incidence of cerebrovascular accident (CVA).
METHODS
Study protocol. We reviewed all electrocardiograms
(ECGs) performed on patients admitted to a tertiary care
teaching hospital during a one-year period from January
1998 to December 1998. All ECGs were recorded on a
Hewlett Packard 1700A and interpreted by one of 16
board-certified cardiologists. Electrocardiograms with the
primary diagnosis of paced rhythm (n 5 305) were exam-
ined for electrocardiographic evidence of underlying AF and
documentation of AF in the physician interpretation. Elec-
trocardiograms in patients with the primary diagnosis of AF
and without a permanent pacemaker were used as controls.
Three board-certified electrophysiologists independently re-
viewed the ECGs. The diagnosis of AF underlying a paced
rhythm was defined as the presence of irregularly irregular
RR intervals with fibrillatory waves during pacer inhibition
or the presence of clear fibrillatory waves and no discernible
P waves between pacemaker spikes on 12 lead ECG. One
hundred eighty-eight of 305 ECGs exhibited underlying
P waves and were excluded from analysis. There was
unanimous agreement among the reviewers on the diagnosis
of AF in 105 of the remaining 117 ECGs (90%) (Fig. 1).
One hundred three of 105 ECGs reflected single chamber
ventricular pacing. Only two cases of dual chamber pacing
during AF were identified (Fig. 2). The corresponding
patient charts were reviewed for identification of AF,
continuous versus intermittent pacing, anticoagulation with
warfarin at discharge, contraindication to anticoagulation
and “optimal use” of anticoagulants. “Optimal use” was
defined as the total number of patients treated with either
warfarin or aspirin, when warfarin was contraindicated.
As a consequence of chart review, 16 of 105 patients were
excluded from analysis. Five patients were noted to be in
sinus rhythm on telemetry or subsequent ECG, three
patients had other indications for anticoagulation, six died
during the hospitalization from unrelated causes, and two
charts were unavailable for review. Analysis was performed
on the remaining 89 paced patients. Fifty randomly selected
unpaced patients with electrocardiographic diagnosis of AF
were used as controls.
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The 139 patients were then divided into three groups: 1)
group A, 30 patients with continuously paced rhythm on
ECG and telemetry and underlying AF, 2) group B,
59 patients with intermittently paced rhythm on ECG or
telemetry and underlying AF, 3) Group C, 50 patients with
persistent AF without an implanted permanent pacemaker.
Patient characteristics (Table 1). Patient charts were re-
viewed to document age, gender, history of hypertension,
diabetes mellitus, presence of organic heart disease (OHD)
and history of CVA/transient ischemic attack. The mean
age of the entire group was 79 6 9 years with 56 women and
83 men. Seventy-seven patients had a history of hyperten-
sion, 22 had a history of diabetes mellitus, 114 had a history
of OHD, and 32 had a history of prior CVA. All patients
had one or more of the following: age . 65 years, hyper-
tension, diabetes mellitus, previous CVA/transient ischemic
attack and congestive heart failure, which placed them at
high risk for thromboembolic phenomena (6,11).
Statistical analysis. Statistical analysis between the three
groups was done using a generalized linear model with the
group as the independent variable and age as the dependent
variable. The categorical variables were examined using a
Pearson chi-square when possible and a Fisher exact test
otherwise. Results are reported as mean 6 standard devia-
tion. A p value less than 0.05 was considered statistically
significant.
RESULTS
Patient characteristics. The mean age of patients was
81 6 8 years in group B, 83 6 9 years in group A and 75 6
9 years in group C. There were no significant differences in
the gender distribution, incidence of diabetes mellitus, prior
CVA or OHD among the three groups. The mean age was
higher in groups A and B compared with group C (p ,
0.001) and the incidence of hypertension lower in group A
versus group C (p , 0.01).
Identification of AF. Atrial fibrillation was identified and
documented within the chart in 6 of 30 patients (20%) in
group A compared with 26 of 59 patients (44%) in group B
and, by definition, all 50 patients in group C. There was a
significant under-recognition of AF in the continuously
paced group (A) when compared with the intermittently
paced group (B) (p , 0.05) or unpaced controls, group (C).
Anticoagulation at discharge. At discharge, 10 of 30
patients (33%) in group A were anticoagulated with warfa-
rin as opposed to 40 of 59 patients (68%) in group B and 27
of 50 patients (54%) in group C. There was a significant
difference between groups A and B and groups A and C;
Figure 1. Unrecognized atrial fibrillation underlying ventricular paced
rhythm. No discernable atrial activity is seen in the lead II rhythm strip;
however, clear fibrillatory waves are seen in precordial lead V1.
Figure 2. Unrecognized atrial fibrillation underlying atrioventricular se-
quential paced rhythm. In the precordial leads there is the appearance of
organized atrial activity followed by ventricular pacing. This was inter-
preted as sinus rhythm with premature atrial depolarization and DDD
pacing. The pacemaker was reprogrammed to VVI revealing the underlying
rhythm to be coarse atrial fibrillation.
Table 1. Patient Demographics
Group A
(n 5 30)
Group B
(n 5 59)
Group C
(n 5 50)
p
Value
Age: mean 6 SD 83 6 9 81 6 8 75 6 9 ,0.001
Female gender 13 (43%) 25 (42%) 18 (36%) NS
History of
hypertension
12 (40%) 31 (53%) 34 (68%) 0.043
History of diabetes
mellitus
2 (7%) 12 (20%) 8 (16%) NS
History of CVA 8 (27%) 9 (15%) 15 (30%) NS
History of OHD 27 (90%) 51 (86%) 36 (72%) NS
CVA 5 cerebrovascular accident; OHD 5 organic heart disease; SD 5 standard
deviation.
Abbreviations and Acronyms
AF 5 atrial fibrillation
CVA 5 cerebrovascular accident
ECG 5 electrocardiogram
OHD 5 organic heart disease
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p , 0.01. Contraindications to warfarin were present in 11
of 30 patients (37%) in group A, 11 of 59 patients (19%) in
group B and 13 of 50 patients (26%) in group C and were
not significantly different among the three groups. In
patients with contraindication to warfarin, aspirin was
prescribed in 2 of 11 patients (18%) in group A, 6 of
11 patients (55%) in group B and 9 of 13 patients (69%) in
group C. The rate of treatment with aspirin was less
frequent in group A compared with group C (p , 0.01);
however, rate of treatment was not different between groups
A and B or between groups B and C. “Optimal use” of
anticoagulants, that is, warfarin or aspirin, when warfarin
was contraindicated was noted in 12 of 30 patients (40%) in
group A, in 46 of 59 patients (78%) in group B and 36 of
50 patients (72%) in group C. There was a significant
difference between groups A and B (p , 0.001) and groups
A and C (p , 0.01; Fig. 2).
DISCUSSION
Identification of AF on ECG. In this analysis of paced
and unpaced patients with AF, we found a statistically lower
incidence of identification of AF in the continuously paced
group (A) versus the intermittent and unpaced groups in
spite of ECG overreading by experienced board-certified
cardiologists. Failure to identify AF may have been due to a
lack of irregularity of the paced rhythm, inability to make
the diagnosis based on presence of fibrillatory waves or
absence of P waves alone or the inappropriate conclusion by
the reader that the underlying rhythm did not require
documentation. In any case the lower rate of identification
of AF parallels the lower rate of anticoagulation and
suggests an excess risk of CVA.
Anticoagulation at discharge. Several large randomized
trials in patients with nonrheumatic AF have demonstrated
a 37% to 86% risk reduction for CVA in groups treated with
oral anticoagulation compared with placebo (1–8). In our
study a higher prevalence of prior CVA was not observed;
however, the sample size was small, the follow-up period
short, a prospective analysis for CVA was not performed,
nor was there any attempt to quantitatively assess prior risk
exposure (e.g., years unprotected AF) between patient
groups. Cerebrovascular accident was evaluated solely by
history, an admittedly crude index. Prior studies attesting to
the benefit of anticoagulation in nonrheumatic AF support
the contention that our study group is at increased risk of
CVA and mitigates against the role of another prospective
trial for this subgroup.
The use of warfarin in patients with AF has been reported
to be 40% to 64% of hospitalized patients without contra-
indication to anticoagulation (12–16). In this report, 54% of
unpaced patients received warfarin although .72% were
“optimally” treated when both warfarin and aspirin were
considered.
Two previous studies address the incidence of anticoag-
ulation in paced patients with underlying AF. Sparks et al.
(17) in a study of 53 high-risk patients with AF and
permanent pacemakers being followed in an outpatient
pacemaker clinic reported that only 8 of 53 patients (15%)
were anticoagulated with warfarin. In an earlier report by
Langenfeld et al. (18), warfarin was used in only 1 of 63
patients (2%) with permanent pacemakers and AF. This
study was published before the randomized trials (1–9)
reporting the benefits of warfarin, which may partially
explain the findings. We report a higher incidence of
warfarin use (56%) in our paced population and “optimal”
treatment with warfarin or aspirin in 65%. The subgroup of
continuously paced patients had the lowest anticoagulation
rate (33%) and rate of “optimal” treatment (40%) and clearly
represents a risk exposed subset.
Study limitations. There are several limitations of this
study. It was not possible to clarify whether the low rate of
identification and documentation of AF, our primary end
point, occurred due a diagnostic problem or a judgement
error. If physicians do not recognize the need to anticoag-
ulate paced patients with underlying AF, identification of
the dysrhythmia will not improve their management.
The link between failure to document AF and the failure
to anticoagulate is implied but not proven. Other factors
may have been responsible for the low rate of anticoagula-
tion, and our assessment of anticoagulation may overesti-
mate the problem somewhat. For the purpose of this study,
we defined “optimal” use of anticoagulation as treatment
with warfarin or aspirin when a contraindication to warfarin
was documented. Our definition of “optimal use” of anti-
coagulants may slightly underestimate a true ideal since
some patients with contraindication to warfarin also have
contraindications to aspirin, and some patients may have
had contraindications that were undocumented or missed in
our survey.
Finally, the failure to note an increased prevalence of
prior CVA in our paced patients was somewhat of a
surprise; however, the groups were small, there was no
prospective follow-up nor was there any attempt to quanti-
tatively assess prior risk exposure (e.g., years unprotected
AF) between patient groups. Nevertheless, we believe the
link between AF and CVA is well established and that
paced patients are at equal or greater risk than their unpaced
counterparts.
Clinical implications. The identification of AF in patients
with predominantly paced rhythm on 12 lead ECG is often
overlooked. We suspect this is due to the absence of an
irregular rhythm. Failure to recognize AF on ECG in
patients with continuous pacing suggests under-recognition
may have made a significant contribution to under-
treatment. Regardless of the reason, that is, failure to
recognize or failure to treat, the incidence of anticoagulation
at discharge was significantly lower in the continuously
paced group compared with the intermittent or unpaced
groups. Although this study did not show an increased
prevalence of prior CVA in the continuously paced sub-
group, there is every reason to anticipate an eventual excess
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incidence of thromboembolic events in this group. We
recommend that all ECGs interpreted as paced rhythms be
examined closely for evidence of underlying AF with par-
ticular attention to continuously paced rhythms. Atrial
fibrillation, if discovered, must be documented and patients
treated according to currently accepted guidelines for anti-
coagulation (19).
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